Extended Data Fig. 6: Oncoprint of mutations identified in the Langerhans Cell Histiocytosis cohort (n = 92 patients).
From: Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms
Results of whole exome and targeted DNA and RNA sequencing of LCH neoplasms. Each patient is represented in one column. Diagnosis (LCH), age category, and sequencing method are in the first 3 rows. Somatic mutations identified are in the lower rows and subdivided based on mutations known to activate kinases, affect the JNK/p38 MAP kinase pathway, or involve a diverse array of co-occurring pathways (shown on the right).
